A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-month outcomes

✍ Scribed by H. Ross; M. Cantarovich; J. Arizon; J. Orus; L. Straatman; J. Howlett; E. Lage; M. Crespo; S. Wang; H. Haddad; L. Pulpon; N. Manito; B. Dı́az Molina; M.A. Gómez

• Book ID: 116518366
• Publisher: Elsevier Science
• Year: 2005
• Tongue: English
• Weight: 66 KB
• Volume: 24
• Category: Article
• ISSN: 1557-3117
• DOI: 10.1016/j.healun.2004.11.085